LabCorp stock hits 52-week high at $258.7 amid robust growth

LabCorp (LH) reached a new 52-week high of $258.7, driven by a 12.16% year-to-date return and a 30.86% increase over the past year, reflecting investor confidence in its diagnostics business. While Q1 2025 revenue of $3.3 billion missed estimates, adjusted EPS of $3.84 beat expectations, and the company reaffirmed its 2025 revenue and free cash flow guidance. Mizuho Securities maintained an Outperform rating, raising the stock target to $274, but InvestingPro's Fair Value analysis suggests the stock may be slightly overvalued at current levels.

Analysis

Laboratory Corporation of America (NYSE:LH) has demonstrated significant market strength, reaching a new 52-week high of $258.7, supported by a 12.16% year-to-date return and a notable 30.86% increase over the past year, reflecting robust investor confidence in its diagnostic capabilities and strategic positioning. This momentum is underpinned by the company's Q1 2025 adjusted earnings per share of $3.84, which surpassed the expected $3.78, despite reported revenue of $3.3 billion falling short of the $3.41 billion forecast, though still achieving a 5.3% year-over-year growth. LabCorp has reaffirmed its full-year 2025 revenue and free cash flow guidance, signaling expectations for margin expansion and continued operational execution, further bolstered by its Launchpad initiative targeting $100-$125 million in cost savings and a strategic focus on high-growth areas such as oncology and women’s health. Analyst sentiment remains broadly positive, with price targets ranging from $248 to $300, and Mizuho Securities maintaining an Outperform rating with an increased target of $274, citing earnings visibility. However, despite a "GOOD" overall financial health score from InvestingPro, its Fair Value analysis suggests the stock may be slightly overvalued at its current record levels.

Key Decisions for Investors

• Investors should weigh LabCorp's strong stock performance, positive analyst sentiment, and reaffirmed guidance against the recent Q1 revenue miss and InvestingPro's indication of slight overvaluation at current highs.
• Monitor upcoming quarterly revenue figures closely to ascertain if the Q1 shortfall was an isolated incident, particularly in light of the company's cost-saving initiatives and focus on high-growth segments which could drive future profitability.
• For existing shareholders, the reaffirmed 2025 guidance and strategic focus on high-growth areas may support a hold strategy, while prospective investors might consider the current valuation against analyst price targets and await further confirmation of revenue acceleration or a more attractive entry point.